1
|
Jebali J, Fakhfekh E, Morgen M, Srairi-Abid N, Majdoub H, Gargouri A, El Ayeb M, Luis J, Marrakchi N, Sarray S. Lebecin, a new C-type lectin like protein from Macrovipera lebetina venom with anti-tumor activity against the breast cancer cell line MDA-MB231. Toxicon 2014; 86:16-27. [PMID: 24814013 DOI: 10.1016/j.toxicon.2014.04.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 04/15/2014] [Accepted: 04/29/2014] [Indexed: 01/20/2023]
Abstract
C-type lectins like proteins display various biological activities and are known to affect especially platelet aggregation. Few of them have been reported to have anti-tumor effects. In this study, we have identified and characterized a new C-type lectin like protein, named lebecin. Lebecin is a heterodimeric protein of 30 kDa. The N-terminal amino acid sequences of both subunits were determined by Edman degradation and the entire amino acid sequences were deduced from cDNAs. The precursors of both lebecin subunits contain a 23-amino acid residue signal peptide and the mature α and β subunits are composed of 129 and 131 amino acids, respectively. Lebecin is shown to be a potent inhibitor of MDA-MB231 human breast cancer cells proliferation. Furthermore, lebecin dose-dependently inhibited the integrin-mediated attachment of these cells to different adhesion substrata. This novel C-type lectin also completely blocked MDA-MB231 cells migration towards fibronectin and fibrinogen in haptotaxis assays.
Collapse
Affiliation(s)
- Jed Jebali
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia.
| | - Emna Fakhfekh
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia
| | - Maram Morgen
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia
| | - Najet Srairi-Abid
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia
| | - Hafedh Majdoub
- USCR séquenceur de protéines, Faculté des sciences de Sfax, Route de Soukra, km 3.5, BP 1171, 3000 Sfax, Tunisia
| | - Ali Gargouri
- Laboratoire de Valorisation de la Biomasse et Production de Protéines chez les Eucaryotes, Centre de la Biotechnologie de Sfax (CBS), Tunisia
| | - Mohamed El Ayeb
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia
| | - José Luis
- Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, UMR_S 911, Marseille, France
| | - Naziha Marrakchi
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia
| | - Sameh Sarray
- Laboratoire des venins et biomolécules thérapeutiques, Institut Pasteur de Tunis, B.P. 74, 1002 Tunis Belvédère, Tunisia; Faculté des Sciences de Tunis, Université de Tunis El Manar, 2092, Tunisia
| |
Collapse
|